© Reuters.
Anaptys, a biotech firm, reported favorable results on Monday from a Phase 3 trial of its investigational drug imsidolimab, aimed at treating generalized pustular psoriasis flares. The drug successfully met its primary objective in the study, providing rapid symptom relief after a single administration of 750mg IV imsidolimab.
The safety profile of imsidolimab was also positive, with all adverse effects reported as mild or moderate. These effects were equally distributed among patients treated with imsidolimab and those given a placebo. Importantly, no serious or severe adverse effects were reported in patients who received the investigational drug.
Following the release of these results, trading of Anaptys’ stock was temporarily halted at $19.25 in premarket trading.
Looking ahead, Anaptys plans to release comprehensive trial data in the second half of 2024 and is on track to submit a biologics license application with the U.S. Food and Drug Administration (FDA) by the third quarter of 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Read the full article here
